Myriad Genetics, Inc (MYGN) concluded trading on Wednesday at a closing price of $4.27, with 12.57 million shares of worth about $53.69 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -76.26% during that period and on May 07, 2025 the price saw a loss of about -41.27%. Currently the company’s common shares owned by public are about 92.20M shares, out of which, 88.14M shares are available for trading.
Stock saw a price change of -42.38% in past 5 days and over the past one month there was a price change of -47.09%. Year-to-date (YTD), MYGN shares are showing a performance of -68.85% which decreased to -78.07% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $6.94 but also hit the highest price of $29.30 during that period. The average intraday trading volume for Myriad Genetics, Inc shares is 1.39 million. The stock is currently trading -42.68% below its 20-day simple moving average (SMA20), while that difference is down -51.47% for SMA50 and it goes to -75.41% lower than SMA200.
Myriad Genetics, Inc (NASDAQ: MYGN) currently have 92.20M outstanding shares and institutions hold larger chunk of about 99.33% of that.
The stock has a current market capitalization of $393.57M and its 3Y-monthly beta is at 2.05. It has posted earnings per share of -$1.12 in the same period. It has Quick Ratio of 1.71 while making debt-to-equity ratio of 0.22. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MYGN, volatility over the week remained 12.96% while standing at 7.93% over the month.
Stock’s fiscal year EPS is expected to drop by -87.36% while it is estimated to increase by 876.93% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Wells Fargo on May 07, 2025 offering an Equal weight rating for the stock and assigned a target price of $6 to it. On March 12, 2025, Piper Sandler Upgrade their recommendations, while on February 12, 2025, Craig Hallum Initiated their ratings for the stock with a price target of $29. Stock get a Neutral rating from UBS on December 10, 2024.
